172 related articles for article (PubMed ID: 37626911)
1. The Adiponectin Receptor Agonist, ALY688: A Promising Therapeutic for Fibrosis in the Dystrophic Muscle.
Dubuisson N; Versele R; Davis-López de Carrizosa MA; Selvais CM; Noel L; Planchon C; Van den Bergh PYK; Brichard SM; Abou-Samra M
Cells; 2023 Aug; 12(16):. PubMed ID: 37626911
[TBL] [Abstract][Full Text] [Related]
2. The slow-release adiponectin analog ALY688-SR modifies early-stage disease development in the D2.
Bellissimo CA; Gandhi S; Castellani LN; Murugathasan M; Delfinis LJ; Thuhan A; Garibotti MC; Seo Y; Rebalka IA; Hsu HH; Sweeney G; Hawke TJ; Abdul-Sater AA; Perry CGR
Am J Physiol Cell Physiol; 2024 Apr; 326(4):C1011-C1026. PubMed ID: 38145301
[TBL] [Abstract][Full Text] [Related]
3. AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy.
Abou-Samra M; Selvais CM; Boursereau R; Lecompte S; Noel L; Brichard SM
J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):518-533. PubMed ID: 31965757
[TBL] [Abstract][Full Text] [Related]
4. Skeletal muscle secretome in Duchenne muscular dystrophy: a pivotal anti-inflammatory role of adiponectin.
Lecompte S; Abou-Samra M; Boursereau R; Noel L; Brichard SM
Cell Mol Life Sci; 2017 Jul; 74(13):2487-2501. PubMed ID: 28188344
[TBL] [Abstract][Full Text] [Related]
5. Memory impairment in the D2.mdx mouse model of Duchenne muscular dystrophy is prevented by the adiponectin receptor agonist ALY688.
Bellissimo CA; Castellani LN; Finch MS; Murugathasan M; Gandhi S; Sweeney G; Abdul-Sater AA; MacPherson REK; Perry CGR
Exp Physiol; 2023 Sep; 108(9):1108-1117. PubMed ID: 37415288
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting the inflammasome with MCC950 counteracts muscle pyroptosis and improves Duchenne muscular dystrophy.
Dubuisson N; Davis-López de Carrizosa MA; Versele R; Selvais CM; Noel L; Van den Bergh PYD; Brichard SM; Abou-Samra M
Front Immunol; 2022; 13():1049076. PubMed ID: 36569900
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of the NLRP3 inflammasome by adiponectin rescues Duchenne muscular dystrophy.
Boursereau R; Abou-Samra M; Lecompte S; Noel L; Brichard SM
BMC Biol; 2018 Mar; 16(1):33. PubMed ID: 29558930
[TBL] [Abstract][Full Text] [Related]
8. Involvement of adiponectin in the pathogenesis of dystrophinopathy.
Abou-Samra M; Lecompte S; Schakman O; Noel L; Many MC; Gailly P; Brichard SM
Skelet Muscle; 2015; 5():25. PubMed ID: 26257862
[TBL] [Abstract][Full Text] [Related]
9. ALY688 elicits adiponectin-mimetic signaling and improves insulin action in skeletal muscle cells.
Sung HK; Mitchell PL; Gross S; Marette A; Sweeney G
Am J Physiol Cell Physiol; 2022 Feb; 322(2):C151-C163. PubMed ID: 34910600
[TBL] [Abstract][Full Text] [Related]
10. Potential Therapeutic Action of Adiponectin in Duchenne Muscular Dystrophy.
Abou-Samra M; Boursereau R; Lecompte S; Noel L; Brichard SM
Am J Pathol; 2017 Jul; 187(7):1577-1585. PubMed ID: 28463682
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotection by the adiponectin receptor agonist ALY688 in a preclinical mouse model of heart failure with reduced ejection fraction (HFrEF).
Cho S; Dadson K; Sung HK; Ayansola O; Mirzaesmaeili A; Noskovicova N; Zhao Y; Cheung K; Radisic M; Hinz B; Sater AAA; Hsu HH; Lopaschuk GD; Sweeney G
Biomed Pharmacother; 2024 Feb; 171():116119. PubMed ID: 38181714
[TBL] [Abstract][Full Text] [Related]
12. A novel blood-based bioassay to monitor adiponectin signaling.
Lone AH; Tang J; Pignalosa A; Hsu HH; Abdul-Sater AA; Sweeney G
Int Immunopharmacol; 2024 May; 132():111890. PubMed ID: 38547772
[TBL] [Abstract][Full Text] [Related]
13. Duchenne muscular dystrophy progression induced by downhill running is accompanied by increased endomysial fibrosis and oxidative damage DNA in muscle of mdx mice.
Lazzarin MC; Dos Santos JF; Quintana HT; Pidone FAM; de Oliveira F
J Mol Histol; 2023 Feb; 54(1):41-54. PubMed ID: 36348131
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic HDAC4 regulates the membrane repair mechanism in Duchenne muscular dystrophy.
Renzini A; Marroncelli N; Cavioli G; Di Francescantonio S; Forcina L; Lambridis A; Di Giorgio E; Valente S; Mai A; Brancolini C; Giampietri C; Magenta A; De Santa F; Adamo S; Coletti D; Moresi V
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1339-1359. PubMed ID: 35170869
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol induces expression of the slow, oxidative phenotype in mdx mouse muscle together with enhanced activity of the SIRT1-PGC-1α axis.
Ljubicic V; Burt M; Lunde JA; Jasmin BJ
Am J Physiol Cell Physiol; 2014 Jul; 307(1):C66-82. PubMed ID: 24760981
[TBL] [Abstract][Full Text] [Related]
17. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
[TBL] [Abstract][Full Text] [Related]
18. The location of protein oxidation in dystrophic skeletal muscle from the mdx mouse model of Duchenne muscular dystrophy.
Iwasaki T; Terrill JR; Kawarai K; Miyata Y; Tagami T; Maeda N; Hasegawa Y; Watanabe T; Grounds MD; Arthur PG
Acta Histochem; 2022 Dec; 124(8):151959. PubMed ID: 36270048
[TBL] [Abstract][Full Text] [Related]
19. A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy.
Whitehead NP; Kim MJ; Bible KL; Adams ME; Froehner SC
Proc Natl Acad Sci U S A; 2015 Oct; 112(41):12864-9. PubMed ID: 26417069
[TBL] [Abstract][Full Text] [Related]
20. ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis.
Riquelme C; Acuña MJ; Torrejón J; Rebolledo D; Cabrera D; Santos RA; Brandan E
PLoS One; 2014; 9(4):e93449. PubMed ID: 24695436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
